AGA seeks damages as Occlutech shuts doors
This article was originally published in Clinica
AGA Medical has initiated proceedings in a German insolvency court to recover damages from rival Occlutech, which has recently closed down its operations. The two companies had a two-year patent dispute that drew to a close earlier in January, after a German court ruled that Occlutech infringed patents held by Minneapolis, Minnesota-based AGA (see Clinica No 1332, p 19). As a result, Occlutech was forced to stop selling its flagship Figulla occluder product and pay AGA damages. Occlutech, of Helsingborg, Sweden, has since terminated all manufacturing and sales and its CEO has resigned, according to AGA. The latter said it has calculated and notified Occlutech the amount of damages that it is seeking.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.